All In Biotech

Drug Trial Radar · NCT02255435

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 172 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

172

Actual

Start

Jan 31, 2015

Primary completion

Oct 31, 2019

Study completion Dec 19, 2025

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie; Friedreich's Ataxia Research Alliance
First posted
Oct 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life. The main questions researchers want to answer in this study are: * How much physical effort can a participant produce during a cycling test after 12 weeks of treatment? * How do scores on the modified Friedreich's Ataxia Rating Scale (mFARS) change after 48 weeks? Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work. They will also use a cycling test to measure physical effort, along with questionnaires to learn how participants feel and function in daily life. Safety will also be tested using physical exams, vital sign checks, echocardiograms (ECHO), electrocardiograms (ECG), and blood and urine tests. The study will be done in 2 main parts, followed by an optional Extension period: * In Part 1, participants will be randomly assigned to take different doses of RTA 408 or a placebo by mouth once a day for 12 weeks. A placebo looks like the study drug but contains no real medicine. * Researchers will compare these doses to decide which one to use in Part 2. * In Part 2, a different group of participants will take either the chosen dose of RTA 408 (150 mg) or placebo once a day for 48 weeks. * Participants who complete Part 1 or Part 2 may be able to join an Extension period, where everyone receives RTA 408. * In the Extension period, participants will continue to receive RTA 408 until the drug becomes commercially available or until they leave the study * Participants in Part 1 will have up to 9 study visits and 2 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 20 weeks. * Participants in Part 2 will have up to 10 study visits and 3 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 61 weeks. * Participants in the Extension period will have 2 visits in the first month, followed by visits every 6 months.

Conditions

  • Friedreich Ataxia

Interventions

  • Omaveloxolone Capsules, 2.5 mgDrug

  • Omaveloxolone Capsules, 5 mgDrug

  • Omaveloxolone Capsules, 10 mgDrug

  • PlaceboDrug

  • Omaveloxolone Capsules, 20 mgDrug

  • Omaveloxolone Capsules, 40 mgDrug

  • Omaveloxolone Capsules, 80 mgDrug

  • Omaveloxolone Capsules, 160 mgDrug

  • Omaveloxolone Capsules, 300 mgDrug

  • Omaveloxolone Capsules, 150 mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 12Time frame: Baseline, Week 12
  2. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From first dose of study drug up to end of Part 1 of the study (up to Week 16)
  3. Part 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48Time frame: Baseline, Week 48
  4. Part 2: Number of Participants With TEAEs and TESAEsTime frame: From first dose of study drug up to end of Part 2 of the study (up to Week 52)

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • University of Florida - Neurology

    Gainesville, Florida

  • USF Ataxia Research Center

    Tampa, Florida

  • Emory University Hospital - Neurology

    Atlanta, Georgia

  • University of Iowa Stead Family Children's Hospital

    Iowa City, Iowa

  • Ohio State University - Neurology

    Columbus, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Murdoch Childrens Research Institute

    Parkville, Victoria, Australia

  • Medical University Innsbruck

    Innsbruck, Austria

  • Neurological Institute Carlo Besta

    Milan, Italy

  • University College of London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.